Pharmaceutical agents for the treatment of cerebral amyloidosis

Details Pharmaceutical agents for the treatment of cerebral amyloidosis Pharmaceutical agents for the treatment of cerebral amyloidosis

C - Chemistry, Metallurgy

07

C

C07C 43/164 (2006.01) A61K 31/08 (2006.01) A61K 31/138 (2006.01) A61K 31/44 (2006.01) A61K 31/495 (2006.01) A61K 31/52 (2006.01) C07C 43/174 (2006.01) C07C 217/10 (2006.01) C07D 211/90 (2006.01) C07D 295/023 (2006.01) C07D 295/03 (2006.01) C07D 295/088 (2006.01) C07D 473/04 (2006.01)

Patent

CA 2290818

Formation of cerebral amyloid associated with Alzheimer's disease can be treated or averted using medicaments that are effective in vivo in preventing disruption of dense microspheres (DMS) or in altering the disruption so as to (i) reduce the volume of tissue occupied by redistributed, transformed DMS protein material and its associated injury focus; (ii) reduce the persistence or duration of injury and inflammation associated with the disrupted DMS and redistributed transformed DMS protein material; and/or (iii) increase the digestion and removal of DMS material through the reticuloendothelial system.

Cette invention concerne un procédé permettant de traiter ou de prévenir la formation d'amyloïde cérébrale associée à la maladie d'Alzheimer. Ce procédé fait appel à des médicaments qui permettent de prévenir efficacement et in vivo la rupture de microsphères denses (MSD), ou d'altérer cette rupture de manière à obtenir les effets suivants: (i) une réduction du volume des tissus occupés par la matière protéinique MSD transformée et de nouveau répartie, et par la zone de blessure qu'elle entraîne; (ii) une réduction de la persistance ou de la durée de la blessure et de l'inflammation associées aux MSD brisées et à la matière protéinique MSD transformée et de nouveau répartie; et/ou (iii) un accroissement de la digestion et de l'élimination de la matière MSD par le système réticulo-endothélial.

Affiliated with

Also associated with

Rating

Pharmaceutical agents for the treatment of cerebral amyloidosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical agents for the treatment of cerebral amyloidosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical agents for the treatment of cerebral amyloidosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1778427